Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Müller-Spahn

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
European Neurology|August 7, 1998
Histological markers in nasal mucosa of patients with Alzheimer's diseaseC Hock, S Golombowski, F Müller-Spahn, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|April 25, 2003
Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment?F Godemann, M Linden, W Gaebel, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1992
Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of GermanyB Bandelow, P Müller, U Frick, et al.
European Neurology|October 29, 2000
Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer's diseaseE Savaskan, F Müller-Spahn, G Olivieri, et al.
Schizophrenia Bulletin|February 5, 2002
A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 yearsM Linden, F Godemann, W Gaebel, et al.
Journal of Pineal Research|November 13, 2001
Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretionG Olivieri, C Hess, E Savaskan, et al.
Psychiatry Research|November 1, 1985
Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathologyD Naber, M Albus, H Bürke, et al.
The British Journal of Psychiatry. Supplement|September 1, 1993
Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?W Gaebel, U Frick, W Köpcke, et al.
Journal of Clinical Psychopharmacology|January 5, 2002
Intranasal administration of delta sleep-inducing peptide increases P300P Hruz, S Zechner, D Heimberg, et al.
Addiction (Abingdon, England)|March 21, 2000
Opioid-associated effects on oxygen saturationK M Dürsteler-Mac Farland, R Störmer, E Seifritz, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
European Neurology|August 7, 1998
Histological markers in nasal mucosa of patients with Alzheimer's diseaseC Hock, S Golombowski, F Müller-Spahn, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|April 25, 2003
Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment?F Godemann, M Linden, W Gaebel, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1992
Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of GermanyB Bandelow, P Müller, U Frick, et al.
European Neurology|October 29, 2000
Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer's diseaseE Savaskan, F Müller-Spahn, G Olivieri, et al.
Schizophrenia Bulletin|February 5, 2002
A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 yearsM Linden, F Godemann, W Gaebel, et al.
Journal of Pineal Research|November 13, 2001
Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretionG Olivieri, C Hess, E Savaskan, et al.
Psychiatry Research|November 1, 1985
Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathologyD Naber, M Albus, H Bürke, et al.
The British Journal of Psychiatry. Supplement|September 1, 1993
Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?W Gaebel, U Frick, W Köpcke, et al.
Journal of Clinical Psychopharmacology|January 5, 2002
Intranasal administration of delta sleep-inducing peptide increases P300P Hruz, S Zechner, D Heimberg, et al.
Addiction (Abingdon, England)|March 21, 2000
Opioid-associated effects on oxygen saturationK M Dürsteler-Mac Farland, R Störmer, E Seifritz, et al.
Pageof 10